FOI disclosure log

Report listing overseas medicine manufacturing sites located in the People’s Republic of China that have been included in an active TGA GMP clearance for sterile injectable (parenteral) vials/bags, covering the manufacture of human medicines.

• FOI 26-2078 (PDF,50.2KB)

Data relating to the supply of vaping products via the Special Access Scheme Category C from 1 October 2024 – 30 September 2025.

• FOI 26-2256 (PDF,132KB)

Data relating to Special Access Scheme and Authorised Prescriber approvals for Levosimendan for infusion for the period 1 January 2024 to 31 July 2025.

• FOI 26-2274 (PDF,63.3KB)

Data relating to Special Access Scheme applications for Metyrapone, Ketoconazole, Tocilizumab, Rituximab and Unituxin for the period 2018 to 29 September 2025.

• FOI 26-2239 (PDF,132.KB)

Documents relating to Iverjohn-12 and Ivervid-12 branded tablets.

• FOI 26-1958 (pdf,2.43MB)

Liber Pharmaceuticals involvement in 2024 vaping reforms.

• FOI 26-1870 (pdf,13.3MB)

Approved carton and vial label artwork for Vidaza Powder for Injection, 100 mg.

• FOI 26-1990 (pdf,368KB)

Data on the number of units of unregistered medicinal cannabis products supplied for the period 1 January 2025 to 30 June 2025.

• FOI 26-2278 (xlsx,49.1KB)

Data on the number of units of unregistered medicinal cannabis products supplied for the period 1 January 2025 to 30 June 2025.

• FOI 26-2142 (xlsx,44KB)

Minutes of the 161st meeting of the Pharmaceutical Sub Committee of the Advisory Committee on Prescription Medicines on 24th March 2015 regarding the matter of preservatives in single use injections.

• FOI 26-2122 (pdf,1.04MB)

Copies of earliest iteration of product packaging for various over-the-counter medications.

• FOI 26-1879 (pdf,4.50MB)

Data relating to Schedule 3 Special Access Scheme (SAS C) pharmacist notifications to TGA of supply of vaping products from 1 October 2024 – 31 August 2025.

• FOI 26-2100 (pdf,650KB)

Data relating to medicinal cannabis SAS-B applications for the period November 2021 to 31 July 2025.

• FOI 26-2102 (xlsx,19.2MB)

Copies of earliest iteration of product packaging for various over-the-counter medications.

• FOI 26-1874 (pdf,7.72MB)

TGA signal notification assessments, signal investigation and signal evaluation documents for the potential safety signals of COVID-19 vaccines for menstrual cycle irregularities/disorders.

• FOI 25-0158 (pdf,2.68MB)

Documents relating to the Complementary and OTC Medicines Regulatory & Technical Forum (ComTech).

• FOI 25-0216 (pdf,13.57MB)

Device Incident Reports (DIR) and documents relating to Stryker Hip Stem (ARTG 145594) and Acetabular Shell (ARTG 152396).

• FOI 25-0214 (pdf,24.6MB)

Carton design, label design, product information and consumer medicine information relating to Depo-Provera (ARTG 12300, 12279 and 401610); and Depo‐Ralovera (ARTG 44464). 

• FOI 25-0197 (pdf,29.81MB)

ARTG Certificates and Registration entries for Nitrostat (AUST R 438851 and 438870) and Anginine (AUST R 11086 and 227783).

• FOI 26-1867 (pdf,1.18MB)

Adverse event data for COVID-19 vaccines from 21 December 2020 to 31 July 2025. 

• FOI 26-1963 (xlsx,2.93MB)

Laboratory reports for Iverheal-12 

• FOI 26-1936 (pdf,0.98MB)

Schedule 3 Special Access Scheme (SAS C) pharmacist notifications to TGA of supply of vaping products from 1 October 2024 – 31 July 2025.

• FOI 26-1978 (pdf,204KB)

Documents relating to the cancellation of Bioglan Astragalus (ARTG ID 289150 from the Australian Register of Therapeutic Goods.

• FOI 26-1889 (pdf,229KB)

GMP Inspection reports for GMP Pharmaceuticals Pty Ltd as the licensed manufacturer. 

• FOI 25-0211 (pdf,1,130KB)

TGA assessment report related to evaluation of ZO-RUB HP capsaicin 0.075% w/w cream tube (AUST R 198783).

• FOI 25-0232 (pdf,5.94MB)

Documentation relating to adverse reactions or potential adverse reactions for therapeutic sunscreens under the brand name Ultra Violette.

• FOI 25-0223 (pdf,703KB)

Documents relating to ARTG 295158 - Intense pulsed light skin surface treatment system.

• FOI 25-0206 (pdf,1.25MB)

Correspondence relating to the processing of FOI 25-0171 between the FOI requester and the TGA.

• FOI 25-0217 (pdf,3.38MB)

Adverse event notifications made to the TGA, and associated correspondence, for all unapproved medicinal cannabis products.

• FOI 26-1890 (pdf,978KB)

Documents related to internal audits conducted by the TGA’s Pharmaceutical Inspectorate.

• FOI 25-0199 (pdf,10.5MB)

Request for application, including any form of supporting documentation for ARTG 488139 – Dr Nature Immunity & Lung Tablet.

• FOI 25-0204 (pdf,1.89MB)

Special Access Scheme data for Cefiderocol for the period 1 January 2020 to 30 June 2025.

• FOI 26-1888 (pdf,223KB)

Toxicity studies of COVID-19 vaccines.

• FOI 2565 (pdf,98.9MB)

Special Access Scheme and Authorised Prescriber data for MDMA/psilocybin for the period 1 July 2023 to 30 June 2025.

• FOI 24-0233 (pdf,74.4KB)

Special Access Scheme (SAS) notifications of vaping supply from 1 October 2024 to 30 June 2025.

• FOI 26-1861 (pdf,88.9KB)

Documents relating to the reintroduction of Zantac in the Australian market.

• FOI 25-0165 (pdf,22.3MB)

Documents relating to menstrual problems following COVID-19 vaccination.

• FOI 25-0040 (pdf,5.93MB)

Spreadsheet containing time-to-death (TTD) data, attenuated to include only the TTD data for adverse event reports where the only coded MedDRA term is ‘adverse event following immunisation’.

• FOI 25-0222 (pdf,39.6KB)

Documents relating to Covid-19 otherwise known as Coronavirus Disease 2019 and SARS-CoV-2.

• FOI 2255 (pdf,11.7MB)

Documents relating to Boston Scientific Pty Ltd pacemakers.

• FOI 25-0417 (pdf,189KB)